Related Experiment Video
Updated: May 29, 2026
05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Telaprevir for chronic hepatitis C with genotype 1: a meta-analysis
Shuang-Suo Dang1, Wen-Jun Wang, Xiu-Fang Wang
1The Department of Infectious Diseases, Xian Jiaotong University, Xian, China. dang212@126.com
Hepato-Gastroenterology
|September 24, 2011
Summary
Telaprevir combined with Peg-interferon alfa-2a and ribavirin improves sustained virological response in chronic hepatitis C genotype 1. The T12PR24 regimen is optimal, but further trials are needed.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis C (HCV) genotype 1 remains a significant global health concern.
- HCV treatment efficacy and safety are critical for patient outcomes.
- Telaprevir, a protease inhibitor, has been investigated for its role in HCV treatment.
Purpose of the Study:
- To evaluate the virological clearance efficacy of telaprevir in genotype 1 chronic hepatitis C.
- To assess the sustained virological response rates associated with telaprevir-based regimens.
- To investigate the safety profile and adverse events related to telaprevir treatment.
Main Methods:
- Meta-analysis of 5 randomized controlled trials involving telaprevir.
- Analysis of end-of-treatment and sustained virological response.
- Assessment of adverse events and treatment discontinuation rates.
Main Results:
- Telaprevir significantly improved virological response in both naive and previously treated patients.
- Triple therapy with telaprevir, Peg-interferon alfa-2a, and ribavirin demonstrated effectiveness.
- Telaprevir use was associated with increased serious adverse events and treatment discontinuations.
- The T12PR24 regimen (telaprevir/PegIFN-2a/ribavirin for 12 weeks, followed by PegIFN-2a/ribavirin for 12 weeks) showed optimal efficiency and duration.
Conclusions:
- Telaprevir combined with Peg-interferon alfa-2a and ribavirin can enhance sustained response in genotype 1 chronic hepatitis C.
- The T12PR24 regimen is identified as a potentially optimal treatment strategy.
- Further randomized controlled trials are necessary to validate these findings.
Related Concept Videos
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
02:33Retroviruses
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...